Pfizer will disclose opioid risks in its promotional activities and will help with public education and disposal efforts; company has provided evidence to Chicago in its litigation against five other opioid manufacturers.
Pfizer Inc. has cooperated with the City of Chicago in a lawsuit the city filed against five other opioid manufacturers in 2014. It has now gone a step further and inked a four-year agreement to follow strict standards in its marketing and promoting of the pain medicines.
Specifically, Pfizer will disclose the risks of opioids in its promotion activities and external communications, including through its sales representatives....
Commissioner Martin Makary told staff that plans are being developed to centralize HR, IT, travel and other functions, which were heavily impacted by the 1 April reduction-in-force.
The House Appropriations Committee wants an analysis of how issues that led to CRLs could have been resolved within the first review cycle and seeks an agency crackdown on counterfeit GLP-1 agonists.
While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.
